Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRIALODINE vs CYTOMEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TRIALODINE is a selective serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that potentiates the effects of serotonin, norepinephrine, and dopamine by blocking their reuptake at presynaptic neurons.
Liothyronine (T3) is a synthetic thyroid hormone that binds to thyroid hormone receptors in the nucleus, altering gene transcription and increasing basal metabolic rate, protein synthesis, and cardiovascular function.
Major depressive disorder (MDD),Generalized anxiety disorder (GAD),Neuropathic pain (off-label)
Primary hypothyroidism (as replacement therapy),Thyroid-stimulating hormone (TSH) suppression in thyroid cancer,Myxedema coma (off-label),Nontoxic goiter (off-label)
50–100 mg orally twice daily; maximum 200 mg/day.
Initial adult dose 25 mcg orally once daily; titrate by 12.5-25 mcg increments every 1-2 weeks based on TSH and clinical response. Usual maintenance dose 50-100 mcg once daily. Maximum dose 100 mcg daily.
Terminal elimination half-life is 6-8 hours in healthy adults; prolongs to 12-15 hours in moderate renal impairment (Cr Cl 30-50 m L/min).
The terminal elimination half-life of liothyronine is approximately 1.0-2.5 days in euthyroid individuals, but may be prolonged in hypothyroidism (up to 3-4 days) and shortened in hyperthyroidism. Clinical context: This short half-life allows rapid dose titration and withdrawal for thyroid suppression tests.
Primarily hepatic via CYP3A4 and CYP2D6 isoenzymes; active metabolite TRIALODINE-M1 contributes to therapeutic effect.
Primarily hepatic conjugation (glucuronidation and sulfation) and minor deiodination; not extensively metabolized by cytochrome P450.
Renal excretion accounts for 70-80% of clearance, primarily as unchanged drug. Biliary/fecal elimination constitutes 15-20%, with the remainder as minor metabolites.
Liothyronine (T3) is primarily eliminated by hepatic metabolism (deiodination and conjugation). Approximately 50-60% of a dose is excreted in urine as metabolites, with less than 5% as unchanged drug. Fecal excretion accounts for about 20-30% via biliary elimination of conjugates.
92-95% bound, primarily to alpha-1-acid glycoprotein and albumin.
99.7% bound to plasma proteins, primarily thyroxine-binding globulin (TBG) (80%), transthyretin (10%), and albumin (10%).
1.5-2.5 L/kg, indicating extensive tissue distribution.
Volume of distribution is approximately 0.4-0.6 L/kg, indicating distribution into total body water. Clinical meaning: Vd is lower than for T4 due to higher protein binding; rapid distribution into tissues occurs.
Oral: 60-70% due to first-pass metabolism; rectal: 80-90%; intravenous: 100%.
Oral bioavailability is approximately 95% (range 90-100%) when taken on an empty stomach; food may slightly reduce absorption. Intravenous bioavailability is 100%.
GFR ≥60 m L/min: no adjustment. GFR 30–59: 50 mg once daily. GFR 15–29: 25 mg once daily. GFR <15: contraindicated.
No specific dose adjustment required for renal impairment.
Child-Pugh A: no adjustment. Child-Pugh B: 50 mg once daily. Child-Pugh C: contraindicated.
No specific dose adjustment required for hepatic impairment; monitor thyroid function closely.
1–2 mg/kg/dose orally twice daily; maximum 4 mg/kg/day (up to 200 mg/day).
Initial 5 mcg orally once daily; increase by 5 mcg every 2-4 weeks based on thyroid function and clinical response. Maintenance: 25-50 mcg once daily. Weight-based: 1.6-2.6 mcg/kg/day.
Initiate at 25 mg once daily; titrate slowly to a maximum of 100 mg/day. Monitor renal function and serum drug levels.
Start with lower initial dose of 12.5-25 mcg orally once daily; titrate slowly (increase by 12.5 mcg every 2-4 weeks) due to increased sensitivity and higher risk of cardiac complications. Monitor TSH closely.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Not approved for weight loss; serious cardiovascular toxicity or death may occur, especially when used with sympathomimetic amines.
May cause serotonin syndrome when used with other serotonergic drugs.,Monitor for increases in blood pressure and heart rate.,Avoid abrupt discontinuation; taper dose to reduce withdrawal symptoms.,Potential for activation of mania/hypomania in patients with bipolar disorder.
Cardiovascular adverse effects (angina, arrhythmias, hypertension, myocardial infarction),Thyrotoxicosis from excessive dosing,May increase anticoagulant effect of warfarin,May reduce glycemic control in diabetes,Bone demineralization with prolonged use
Concomitant use with MAOIs or within 14 days of MAOI therapy.,Uncontrolled narrow-angle glaucoma.,Hypersensitivity to TRIALODINE or any excipients.
Untreated thyrotoxicosis,Acute myocardial infarction,Uncorrected adrenal insufficiency
Avoid grapefruit and grapefruit juice as they may increase TRIALODINE levels by inhibiting CYP3A4. High-fat meals may delay absorption; take consistently with or without food. Avoid alcohol.
High-fiber foods, walnuts, soybean flour, and cottonseed meal may reduce absorption. Avoid excessive intake of iodine-rich foods (e.g., kelp, seaweed). Maintain consistent dietary habits for stable drug absorption.
First trimester: Limited human data; animal studies at 10x MRHD show skeletal anomalies (rib fusion, vertebral malformations). Second trimester: No specific pattern identified but risk of fetal growth restriction. Third trimester: May cause premature closure of ductus arteriosus (risk of persistent pulmonary hypertension) and oligohydramnios due to fetal renal effects.
Pregnancy category A. Thyroid hormones do not readily cross the placenta in early pregnancy; insufficient maternal thyroid hormone may cause fetal neurodevelopmental deficits. In first trimester, untreated maternal hypothyroidism linked to miscarriage and fetal anomalies; replacement therapy reduces risk. Second and third trimesters: maternal hypothyroidism associated with preterm birth, low birth weight, and impaired cognitive development; adequate dosing is critical. No evidence of teratogenicity at therapeutic doses.
Excreted in human milk (M/P ratio 1.2). Peak milk concentration 2 hours post-dose. Relative infant dose 8% of maternal weight-adjusted dose. Avoid breastfeeding due to potential for infant hypotension and renal impairment.
Liothyronine (T3) is excreted into human breast milk in low concentrations; M/P ratio not established. Exogenous T3 may suppress endogenous maternal thyroid function. Benefits of breastfeeding generally outweigh minimal risk; infant thyroid function should be monitored if mother requires high doses. Use with caution.
Clearance increases by 40% in second trimester and 50% in third trimester. Starting dose may need to be titrated upward (e.g., 1.5-fold increase) to maintain therapeutic effect. Monitor drug levels with target trough concentration 5-10 mcg/m L.
Pregnancy increases T3 clearance and decreases serum T3 levels. Dose requirements may increase by 30–50% compared to prepregnancy baseline. Frequent monitoring of free T3 and TSH is required; adjust dose to maintain free T3 in the upper normal range and TSH within trimester-specific targets. Dose adjustments should be made in increments of 5–12.5 mcg daily. Postpartum, dose usually returns to prepregnancy levels.
TRIALODINE is a synthetic opioid analgesic; monitor for respiratory depression especially in opioid-naïve patients and those with COPD. Due to its long half-life (24-48 hours), dose titration should be gradual. Avoid in patients with paralytic ileus or suspected surgical abdomen. Contraindicated in patients with known hypersensitivity to triazoline opioids. In renal impairment (Cr Cl <30 m L/min), reduce dose by 50%.
Initiate at low doses (5-12.5 mcg/day) in elderly or cardiac patients; increase gradually every 1-2 weeks. Monitor TSH, T3, and T4 levels; T3 therapy can cause rapid swings in thyroid hormone levels. Use with caution in adrenal insufficiency, coronary artery disease, or diabetes insipidus. May increase warfarin sensitivity; reduce anticoagulant dose. Discontinue 2-4 weeks before thyroid uptake scans.
Do not crush or chew extended-release tablets; swallow whole.,Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines) due to risk of severe sedation and respiratory depression.,Do not stop abruptly; withdrawal symptoms (e.g., anxiety, sweating, diarrhea) may occur.,Store in a secure place out of reach of children; do not share medication.,May cause constipation; increase fluid and fiber intake, and consider stool softeners if needed.,Report dizziness, slow heart rate, or difficulty breathing immediately.,Do not drive or operate machinery until you know how TRIALODINE affects you.
Take exactly as prescribed; do not change dose without consulting your doctor.,Take on an empty stomach, at least 30 minutes before food or other medications.,Notify your doctor if you experience chest pain, rapid heartbeat, nervousness, or excessive sweating.,Do not stop suddenly; abrupt withdrawal can cause hypothyroid symptoms.,Inform all healthcare providers you are taking this medication.,May increase sensitivity to blood thinners; report signs of bleeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRIALODINE vs CYTOMEL, answered by our medical review team.
TRIALODINE is a Thyroid Hormone that works by TRIALODINE is a selective serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that potentiates the effects of serotonin, norepinephrine, and dopamine by blocking their reuptake at presynaptic neurons.. CYTOMEL is a Thyroid Hormone that works by Liothyronine (T3) is a synthetic thyroid hormone that binds to thyroid hormone receptors in the nucleus, altering gene transcription and increasing basal metabolic rate, protein synthesis, and cardiovascular function.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRIALODINE and CYTOMEL depend on the specific clinical indication. These are both Thyroid Hormone agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRIALODINE is: 50–100 mg orally twice daily; maximum 200 mg/day.. The standard adult dose of CYTOMEL is: Initial adult dose 25 mcg orally once daily; titrate by 12.5-25 mcg increments every 1-2 weeks based on TSH and clinical response. Usual maintenance dose 50-100 mcg once daily. Maximum dose 100 mcg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRIALODINE and CYTOMEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRIALODINE is classified as Category C. First trimester: Limited human data; animal studies at 10x MRHD show skeletal anomalies (rib fusion, vertebral malformations). Second trimester: No specific pattern identified but . CYTOMEL is classified as Category C. Pregnancy category A. Thyroid hormones do not readily cross the placenta in early pregnancy; insufficient maternal thyroid hormone may cause fetal neurodevelopmental deficits. In f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.